Home MS CureMS Treatments MS Review of Ocrelizumab + Q&A with Dr. Tim Vollmer

MS Review of Ocrelizumab + Q&A with Dr. Tim Vollmer

by admin


 
The FDA officially approved Ocrelizumab (brand name: Ocrevus) for use in multiple sclerosis treatment on March 28, 2017. In this live MS Q&A, Dr. Tim Vollmer answers many interesting questions on this new treatment option for MS patients.

Interesting Note:
A study of rituximab in MS with strong results, published in the New England Journal of Medicine in 2008, drove interest in B-cell depletion as a strategy to treat MS and has led to extensive off-label use of rituximab to treat primary and relapsing MS. Rituximab is a mouse protein, and is immunogenic in humans, and Genentech and its parent Roche decided to focus on the similar, but humanized mAb that they already had, Ocrelizumab, for MS instead.

Related Posts

We use cookies to personalize content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services Accept Read More